FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147153171> ?p ?o ?g. }

• W2147153171 endingPage "44" @default.
• W2147153171 startingPage "2537" @default.
• W2147153171 abstract "Protein kinase A type I (PKAI) plays a key role in neoplastic transformation, conveys mitogenic signals from different sources, and is overexpressed in the majority of human tumors. Inhibition of PKAI by different tools results in cancer-cell growth inhibition in vitro and in vivo. We and others have recently shown that a novel class of mixed-backbone oligonucleotides targeting the PKAI subunit RIalpha exhibits improved pharmacokinetic properties and antitumor activity accompanied by increased apoptosis in several human cancer types in vitro and in vivo. The role of bcl-2 in the control of apoptosis has been widely documented, and the inhibition of bcl-2 expression and function may have important therapeutic implications. In fact, oligonucleotides antisense bcl-2 have shown antitumor activity in animal models and have successfully completed early clinical trials. Recent studies have demonstrated a direct role of PKA in the regulation of the bcl-2-dependent apoptotic pathway. Therefore, we have investigated the combined blockade of PKA and bcl-2 by antisense strategy as a potential therapeutic approach. The novel hybrid DNA/RNA mixed-backbone oligonucleotide antisense RIalpha (AS RIalpha) in combination with the antisense bcl-2 (AS bcl-2), cooperatively inhibited bcl-2 expression and soft agar growth and induced apoptosis in different human cancer cell lines. p.o. administration of AS RIalpha in combination with i.p. AS bcl-2 caused a marked antitumor effect and a significant prolongation of survival in nude mice bearing human colon cancer xenografts. Moreover, histochemical analysis of tumor specimens showed inhibition of RIalpha and Ki67 expression, inhibition of angiogenesis, and parallel induction of apoptosis in vivo. The results of our study imply an interaction between the PKA and bcl-2 signaling pathways and, because both antisenses have now entered Phase II trials, provide the rationale to translate this novel therapeutic strategy in a clinical setting." @default.
• W2147153171 created "2016-06-24" @default.
• W2147153171 creator A5015371717 @default.
• W2147153171 creator A5017474339 @default.
• W2147153171 creator A5038671879 @default.
• W2147153171 creator A5040413764 @default.
• W2147153171 creator A5043155650 @default.
• W2147153171 creator A5050215401 @default.
• W2147153171 creator A5071099107 @default.
• W2147153171 creator A5078562748 @default.
• W2147153171 creator A5087739912 @default.
• W2147153171 date "2001-08-01" @default.
• W2147153171 modified "2023-09-26" @default.
• W2147153171 title "Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis." @default.
• W2147153171 cites W1199216903 @default.
• W2147153171 cites W137489454 @default.
• W2147153171 cites W1533077869 @default.
• W2147153171 cites W1588936614 @default.
• W2147153171 cites W1823288226 @default.
• W2147153171 cites W1865619950 @default.
• W2147153171 cites W1870720170 @default.
• W2147153171 cites W187223960 @default.
• W2147153171 cites W1976419136 @default.
• W2147153171 cites W1997410071 @default.
• W2147153171 cites W2001453148 @default.
• W2147153171 cites W2009240587 @default.
• W2147153171 cites W2019732628 @default.
• W2147153171 cites W2042760441 @default.
• W2147153171 cites W2046573564 @default.
• W2147153171 cites W2046867705 @default.
• W2147153171 cites W2048997359 @default.
• W2147153171 cites W2056543772 @default.
• W2147153171 cites W2057320402 @default.
• W2147153171 cites W2060865922 @default.
• W2147153171 cites W2074312161 @default.
• W2147153171 cites W2088900497 @default.
• W2147153171 cites W2101961850 @default.
• W2147153171 cites W2104890635 @default.
• W2147153171 cites W2106764013 @default.
• W2147153171 cites W2109990295 @default.
• W2147153171 cites W2113211717 @default.
• W2147153171 cites W2119429641 @default.
• W2147153171 cites W2119792005 @default.
• W2147153171 cites W2132411546 @default.
• W2147153171 cites W2139984188 @default.
• W2147153171 cites W2145888569 @default.
• W2147153171 cites W2147730561 @default.
• W2147153171 cites W2151220251 @default.
• W2147153171 cites W2158730778 @default.
• W2147153171 cites W2290539832 @default.
• W2147153171 cites W2331400535 @default.
• W2147153171 cites W2092594414 @default.
• W2147153171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11489837" @default.
• W2147153171 hasPublicationYear "2001" @default.
• W2147153171 type Work @default.
• W2147153171 sameAs 2147153171 @default.
• W2147153171 citedByCount "9" @default.
• W2147153171 crossrefType "journal-article" @default.
• W2147153171 hasAuthorship W2147153171A5015371717 @default.
• W2147153171 hasAuthorship W2147153171A5017474339 @default.
• W2147153171 hasAuthorship W2147153171A5038671879 @default.
• W2147153171 hasAuthorship W2147153171A5040413764 @default.
• W2147153171 hasAuthorship W2147153171A5043155650 @default.
• W2147153171 hasAuthorship W2147153171A5050215401 @default.
• W2147153171 hasAuthorship W2147153171A5071099107 @default.
• W2147153171 hasAuthorship W2147153171A5078562748 @default.
• W2147153171 hasAuthorship W2147153171A5087739912 @default.
• W2147153171 hasConcept C121608353 @default.
• W2147153171 hasConcept C150903083 @default.
• W2147153171 hasConcept C184235292 @default.
• W2147153171 hasConcept C190283241 @default.
• W2147153171 hasConcept C207001950 @default.
• W2147153171 hasConcept C2779707156 @default.
• W2147153171 hasConcept C2780394083 @default.
• W2147153171 hasConcept C502942594 @default.
• W2147153171 hasConcept C54355233 @default.
• W2147153171 hasConcept C55493867 @default.
• W2147153171 hasConcept C62112901 @default.
• W2147153171 hasConcept C86803240 @default.
• W2147153171 hasConcept C95444343 @default.
• W2147153171 hasConcept C97029542 @default.
• W2147153171 hasConcept C98274493 @default.
• W2147153171 hasConceptScore W2147153171C121608353 @default.
• W2147153171 hasConceptScore W2147153171C150903083 @default.
• W2147153171 hasConceptScore W2147153171C184235292 @default.
• W2147153171 hasConceptScore W2147153171C190283241 @default.
• W2147153171 hasConceptScore W2147153171C207001950 @default.
• W2147153171 hasConceptScore W2147153171C2779707156 @default.
• W2147153171 hasConceptScore W2147153171C2780394083 @default.
• W2147153171 hasConceptScore W2147153171C502942594 @default.
• W2147153171 hasConceptScore W2147153171C54355233 @default.
• W2147153171 hasConceptScore W2147153171C55493867 @default.
• W2147153171 hasConceptScore W2147153171C62112901 @default.
• W2147153171 hasConceptScore W2147153171C86803240 @default.
• W2147153171 hasConceptScore W2147153171C95444343 @default.
• W2147153171 hasConceptScore W2147153171C97029542 @default.
• W2147153171 hasConceptScore W2147153171C98274493 @default.
• W2147153171 hasIssue "8" @default.

• next